Impact of Anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC) trial
We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). The prognostic importance of anemia on primary PCI outcomes is unknown. In the Controlled Abciximab and Device Investigation to Lower Late Ang...
Gespeichert in:
Veröffentlicht in: | Journal of the American College of Cardiology 2004-08, Vol.44 (3), p.547-553 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI).
The prognostic importance of anemia on primary PCI outcomes is unknown.
In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 2,082 patients of any age with AMI within 12 h onset undergoing primary PCI were randomized to balloon angioplasty versus stenting, each +/- abciximab. Outcomes were stratified by the presence of anemia at baseline, as defined by World Health Organization criteria (hematocrit |
---|---|
ISSN: | 0735-1097 1558-3597 |
DOI: | 10.1016/j.jacc.2004.03.080 |